How can one feel 'achchhe din': Patanjali over high GST on ayurvedic items

The high tax under GST will make natural medicines costly, out of reach for common people: AMAM

GST, tax
Press Trust of India New Delhi
Last Updated : May 28 2017 | 3:45 PM IST
Disappointed over high GST rate on ayurvedic products that provide "care and cure to common man at affordable price", Baba Ramdev-led Patanjali Ayurved has asked the government as to how can people feel and live 'Achchhe Din' without the right to good health.

In a similar vein, industry body AMAM also said that while the government is aggressively promoting ayurveda globally, high tax incidence under GST will make the natural medicines costly and out of reach of the common people back home.

GST rate for classical or generic range of ayurvedic medicines must be nil and 5 per cent for patented products instead of the proposed 12 per cent, the Association of Manufacturers of Ayurvedic Medicines (AMAM) has said.

At present the ayurvedic medicines and products have a total tax incidence of 7 per cent, including VAT, depending on the items. Under the GST regime, these items have been kept at 12 per cent.

"Higher GST on ayurvedic category has surprised us and is very disappointing and disheartening," Patanjali Ayurved Ltd and Patanjali Yogpeeth spokesman S K Tijarawala told PTI in an emailed response.

He further said Ayurveda, which provides care and cure to the common man at an affordable price and is ancient and proven therapy for ages, doesn't deserve such treatment.

"Good health and healthy living is common man's basic right and expectation. Without all these, how can one feel and live 'Achchhe Din'?" he said.

Echoing similar sentiments, AMAM General Secretary Pradeep Multani said: "The Indian government has been aggressively promoting ayurvedic products internationally but what's the point of doing these things when the tax rate is so high and the common people can't afford it at home?"

He further said: "This is sad and unfortunate as the Prime Minister is doing his best to boost the AYUSH system."

The previous UPA government "treated Ayurveda industry as step child" but this government has taken steps to take it forward, Multani said, however, adding the high tax rate proposed under GST "will make Ayurvedic, Sidha and Unani medicines out of reach of common man and kill the system".

He said if homoeopathic products could be put under 5 per cent slab under GST, ayurvedic products should also be kept under the rate.

Tijarawala said the world is now looking forward to Indian vedic knowledge of Ayurveda. It has created a new potential of over Rs 1 lakh crore market for such natural and healthy products.

Prime Minister Narendra Modi had recently even inaugurated Patanjali Research Institute (PRI) established with an outlay of over Rs 250 crore for R&D in the field of Ayurved, he added.

"We have created a lead being followed by so many other companies. This has opened new avenues of self employment generation in the field of herbicultutre, agriculture, ayurved practitioners, naturopathy, ayurveda product manufacturing," Tijarawala said.

Earlier, FMCG major Dabur India also expressed disappointment with the new tax structure saying it will have an adverse impact on the Ayurvedic medicines category.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: May 28 2017 | 3:42 PM IST

Next Story